Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.
about
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumabAquaporin 4 and neuromyelitis opticaFingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceTh17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic ImplicationsTherapy of NMO spectrum disordersUltrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease managementInternational consensus diagnostic criteria for neuromyelitis optica spectrum disordersImmunology of neuromyelitis optica: a T cell-B cell collaborationConventional and advanced imaging in neuromyelitis opticaMRI characteristics of neuromyelitis optica spectrum disorder: an international updateTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesLongitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosisEvaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serologyOverview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Optic neuritis in neuromyelitis optica.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.[Ultrahigh field MRI in context of neurological diseases].Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature.Recurrent Longitudinally Extensive Myelitis and Aquaporin-4 Seronegativity - The Expanding Spectrum of Neuromyelitis Optica.Differential diagnosis of neuromyelitis optica spectrum disorders.The treatment of neuromyelitis optica.The frequency of anti-aquaporin-4 Ig g antibody in neuromyelitis optica and its spectrum disorders at a single tertiary referral center in malaysia.Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Unmasking and provoking severe disease activity in a patient with NMO spectrum disorderPeripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.B lymphocytes in neuromyelitis opticaThe Correlation between Aquaporin-4 Antibody and the Visual Function of Patients with Demyelinating Optic Neuritis at Onset.The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.Neuromyelitis optica (NMO) and autoimmune thyroiditis.Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension studyPresent and Future Therapies in Neuromyelitis Optica Spectrum DisordersRituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorderEpigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.Three cases of neuromyelitis optica spectrum disorderImmunoadsorption in patients with neuromyelitis optica spectrum disorder.Immunotherapy of neuromyelitis optica.
P2860
Q24598109-84CFE317-47F1-490D-8572-E72675F2A167Q24613666-6B54B762-EE49-4E11-A577-6C8A48B3E5D4Q26752466-EB01F9DA-B3F0-43AA-B12E-4CE56FF7CD3AQ26768649-0F3CAB66-9C80-4FC7-8DDC-9E9325F270B6Q26779910-2A189BCA-48BC-4A57-A0D0-615655AE05EAQ26796643-67415772-2EE5-43F7-A9F0-ACECB0309337Q26824579-A25D1038-CB3E-40F2-ADED-0A70917E7942Q27016045-4EFC79B7-578C-4B41-BF75-E3E891E9BC75Q27021822-6EFA26E3-A693-4932-8961-E1EDFBC12DD9Q28087067-85DF8A11-09B9-4685-A6AB-1F2E6805AF30Q28245749-F3E1952E-86BC-460C-B0AE-54CDE5101F77Q28647496-5280C9C0-96C7-4E5F-9299-287D2FFD768DQ28728565-CD1302F2-3692-4337-88F9-76B0A573DF0AQ30458371-E7058D6C-9E14-4DA6-876F-E2FC0F7DA55DQ30577078-1D91E1B1-92EB-449D-8EB1-5758CC28D0C7Q30610471-20B65BB5-2A1C-4B45-8700-EC046D8BF3CAQ30676331-09B95E6A-7A11-413C-8F46-9A57059DCA45Q30759627-822DEF99-47F1-4280-B2B5-07C93FA973C2Q30785267-76490E4C-BE78-46C7-8AF2-72EFAC837B20Q33734731-CC2219FD-5741-4AC2-BF3F-675892F27219Q33741772-C7C28091-B409-4C1A-965D-837B9789015DQ33812063-28576541-C569-4B4A-8CFF-D6F30841BF05Q34399291-C262E73C-D408-49FC-9C32-30CD7F6887BEQ34762744-1F8FA024-E17C-416B-861E-44F304B679B2Q34785270-FBB17789-266A-4E5F-86B2-B97C92AD0593Q35052199-3921B7B8-DE29-4383-9896-8C7256862387Q35105745-94771F19-3196-4C10-A255-1EC3632717B4Q35547287-A0EC0E0F-8A4A-488D-9577-11AFBD1B7987Q35591039-524744F1-DBB9-41E2-A73E-2A65C29E7600Q35640735-2C04F886-1AF4-4BEF-B4AB-185021601FC1Q36171516-4AE1FB10-D8D5-4025-8AA0-2AF3A428FB23Q36226577-0D2CF42B-8F9B-498A-9EF4-828D272721EFQ36262843-95A774DB-7E44-4A41-AC5C-FD55E6632836Q36484394-CACBC554-D7B3-4C75-B72C-CA26DBBDDA63Q36490876-FD43E12F-ED4B-441D-92DA-F10D4A99A7BBQ36648907-5531B763-2ED0-423D-BC2A-1A8DF62C8997Q36753462-6CCD68CF-A065-49F4-A8E4-D3A59B124C02Q36953630-4E5AAECB-4496-4113-A473-C9A1165C934BQ37027700-9FA92A26-A0D0-4145-B5E8-CE6DD74AFEC4Q37456974-4731F689-512D-460B-A709-9447E113A3DB
P2860
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Development of extensive brain ...... itis optica spectrum disorder.
@en
Development of extensive brain lesions following fingolimod
@nl
type
label
Development of extensive brain ...... itis optica spectrum disorder.
@en
Development of extensive brain lesions following fingolimod
@nl
prefLabel
Development of extensive brain ...... itis optica spectrum disorder.
@en
Development of extensive brain lesions following fingolimod
@nl
P2093
P2860
P356
P1476
Development of extensive brain ...... itis optica spectrum disorder.
@en
P2093
Byoung Joon Kim
Ju-Hong Min
Kwang Ho Lee
P2860
P304
P356
10.1177/1352458511431973
P577
2011-12-06T00:00:00Z